These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 34429310)

  • 1. Effect of phosphodiesterase-type 5 inhibitors on erectile function: an overview of systematic reviews and meta-analyses.
    Pyrgidis N; Mykoniatis I; Haidich AB; Tirta M; Talimtzi P; Kalyvianakis D; Ouranidis A; Hatzichristou D
    BMJ Open; 2021 Aug; 11(8):e047396. PubMed ID: 34429310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effect of Phosphodiesterase-type 5 Inhibitors on Erectile Function: An Overview of Systematic Reviews.
    Pyrgidis N; Mykoniatis I; Haidich AB; Tirta M; Talimtzi P; Kalyvianakis D; Ouranidis A; Hatzichristou D
    Front Pharmacol; 2021; 12():735708. PubMed ID: 34557099
    [No Abstract]   [Full Text] [Related]  

  • 3. Systematic Review of Oral Combination Therapy for Erectile Dysfunction When Phosphodiesterase Type 5 Inhibitor Monotherapy Fails.
    Munk NE; Knudsen JS; Comerma-Steffensen S; Simonsen U
    Sex Med Rev; 2019 Jul; 7(3):430-441. PubMed ID: 30711478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of oral phosphodiesterase 5 inhibitors for erectile dysfunction: a network meta-analysis and multicriteria decision analysis.
    Madeira CR; Tonin FS; Fachi MM; Borba HH; Ferreira VL; Leonart LP; Bonetti AF; Moritz RP; Trindade ACLB; Gonçalves AG; Fernandez-Llimos F; Pontarolo R
    World J Urol; 2021 Mar; 39(3):953-962. PubMed ID: 32388784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphodiesterase 5 inhibitors for the treatment of erectile dysfunction: a trade-off network meta-analysis.
    Chen L; Staubli SE; Schneider MP; Kessels AG; Ivic S; Bachmann LM; Kessler TM
    Eur Urol; 2015 Oct; 68(4):674-80. PubMed ID: 25817916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Placebo Responses Among Men With Erectile Dysfunction Enrolled in Phosphodiesterase 5 Inhibitor Trials: A Systematic Review and Meta-analysis.
    Stridh A; Pontén M; Arver S; Kirsch I; Abé C; Jensen KB
    JAMA Netw Open; 2020 Mar; 3(3):e201423. PubMed ID: 32196105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of Combination Therapies vs Monotherapy for Erectile Dysfunction: A Systematic Review and Meta-analysis.
    Mykoniatis I; Pyrgidis N; Sokolakis I; Ouranidis A; Sountoulides P; Haidich AB; van Renterghem K; Hatzichristodoulou G; Hatzichristou D
    JAMA Netw Open; 2021 Feb; 4(2):e2036337. PubMed ID: 33599772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphodiesterase-5 inhibitors could be efficacious in the treatment of erectile dysfunction after radiotherapy for prostate cancer: a systematic review and meta-analysis.
    Yang L; Qian S; Liu L; Pu C; Yuan H; Han P; Wei Q
    Urol Int; 2013; 90(3):339-47. PubMed ID: 23221333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erectile function recovery in men treated with phosphodiesterase type 5 inhibitor administration after bilateral nerve-sparing radical prostatectomy: a systematic review of placebo-controlled randomized trials with trial sequential analysis.
    Limoncin E; Gravina GL; Corona G; Maggi M; Ciocca G; Lenzi A; Jannini EA
    Andrology; 2017 Sep; 5(5):863-872. PubMed ID: 28787547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The safety and efficacy of PDE5-inhibitors-vardenafil on treating diabetes mellitus erectile dysfunction: A protocol for systematic review and meta analysis.
    He J; Li X; Dai HH; Wang JS; Li HS; Zhang XJ; Wang P; Zhang D; Zuo LY; Xie N; Li Y
    Medicine (Baltimore); 2019 Dec; 98(51):e18361. PubMed ID: 31860994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of PDE5 inhibitors in the treatment of diabetes mellitus erectile dysfunction: Protocol for a systematic review.
    Li X; Zhao Q; Wang J; Wang J; Dai H; Li H; Wang B
    Medicine (Baltimore); 2018 Oct; 97(40):e12559. PubMed ID: 30290616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of phosphodiesterase-5 inhibitors (PDE5is) on the treatment of male infertility: A protocol for systematic review and meta-analysis.
    Dong L; Zhang X; Yan X; Shen Y; Yu X; Li Y
    Medicine (Baltimore); 2019 Dec; 98(50):e18317. PubMed ID: 31852117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis.
    Yuan J; Zhang R; Yang Z; Lee J; Liu Y; Tian J; Qin X; Ren Z; Ding H; Chen Q; Mao C; Tang J
    Eur Urol; 2013 May; 63(5):902-12. PubMed ID: 23395275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-generation phosphodiesterase type 5 inhibitors dropout: a comprehensive review and meta-analysis.
    Corona G; Rastrelli G; Burri A; Serra E; Gianfrilli D; Mannucci E; Jannini EA; Maggi M
    Andrology; 2016 Nov; 4(6):1002-1009. PubMed ID: 27636710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effects of phosphodiesterase-5 inhibitors on cardiovascular outcomes and death: a systematic review and meta-analysis.
    Soulaidopoulos S; Terentes-Printzios D; Ioakeimidis N; Tsioufis KP; Vlachopoulos C
    Eur Heart J Cardiovasc Pharmacother; 2024 Aug; 10(5):403-412. PubMed ID: 38777751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy and safety of phosphodiesterase type 5 inhibitors for erectile dysfunction in diabetic men: a Bayesian network meta-analysis of randomized controlled trials.
    Liao X; Qiu S; Bao Y; Wang W; Yang L; Wei Q
    World J Urol; 2019 Jun; 37(6):1061-1074. PubMed ID: 30523399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Quality of Systematic Reviews and Meta-Analyses in Erectile Dysfunction Treatment and Management Published in the Sexual Medicine Literature.
    Greenberg DR; Richardson MT; Tijerina JD; Bass MB; Eisenberg ML
    J Sex Med; 2019 Mar; 16(3):394-401. PubMed ID: 30773501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is chronic inhibition of phosphodiesterase type 5 cardioprotective and safe? A meta-analysis of randomized controlled trials.
    Giannetta E; Feola T; Gianfrilli D; Pofi R; Dall'Armi V; Badagliacca R; Barbagallo F; Lenzi A; Isidori AM
    BMC Med; 2014 Oct; 12():185. PubMed ID: 25330139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of levetiracetam in children with epilepsy: protocol for an umbrella review of systematic reviews and meta-analyses of randomised controlled trials.
    Gan J; Ma D; Xiong T
    BMJ Open; 2019 Jul; 9(7):e029811. PubMed ID: 31296513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of Melanoma With Phosphodiesterase Type 5 Inhibitor Use Among Patients With Erectile Dysfunction, Pulmonary Hypertension, and Lower Urinary Tract Symptoms.
    Shkolyar E; Li S; Tang J; Eisenberg ML
    J Sex Med; 2018 Jul; 15(7):982-989. PubMed ID: 29884444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.